Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1969 2
1970 1
1972 1
1979 1
1980 1
1982 2
1983 1
1984 2
1986 1
1989 1
1990 4
1991 5
1992 3
1993 3
1994 1
1995 2
1996 6
1997 7
1998 6
1999 12
2000 14
2001 5
2002 9
2003 10
2004 8
2005 7
2006 9
2007 8
2008 13
2009 17
2010 14
2011 21
2012 22
2013 26
2014 21
2015 23
2016 21
2017 31
2018 32
2019 28
2020 47
2021 42
2022 20
Text availability
Article attribute
Article type
Publication date

Search Results

445 results
Results by year
Filters applied: . Clear all
Page 1
Haemophilia B: Where are we now and what does the future hold?
Dolan G, Benson G, Duffy A, Hermans C, Jiménez-Yuste V, Lambert T, Ljung R, Morfini M, Zupančić Šalek S. Dolan G, et al. Among authors: hermans c. Blood Rev. 2018 Jan;32(1):52-60. doi: 10.1016/j.blre.2017.08.007. Epub 2017 Aug 16. Blood Rev. 2018. PMID: 28826659 Review.
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Judson I, Verweij J, Gelderblom H, Hartmann JT, Schöffski P, Blay JY, Kerst JM, Sufliarsky J, Whelan J, Hohenberger P, Krarup-Hansen A, Alcindor T, Marreaud S, Litière S, Hermans C, Fisher C, Hogendoorn PC, dei Tos AP, van der Graaf WT; European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Judson I, et al. Among authors: hermans c. Lancet Oncol. 2014 Apr;15(4):415-23. doi: 10.1016/S1470-2045(14)70063-4. Epub 2014 Mar 5. Lancet Oncol. 2014. PMID: 24618336 Clinical Trial.
Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
Pipe SW, Shima M, Lehle M, Shapiro A, Chebon S, Fukutake K, Key NS, Portron A, Schmitt C, Podolak-Dawidziak M, Selak Bienz N, Hermans C, Campinha-Bacote A, Kiialainen A, Peerlinck K, Levy GG, Jiménez-Yuste V. Pipe SW, et al. Among authors: hermans c. Lancet Haematol. 2019 Jun;6(6):e295-e305. doi: 10.1016/S2352-3026(19)30054-7. Epub 2019 Apr 16. Lancet Haematol. 2019. PMID: 31003963 Clinical Trial.
Auranofin reveals therapeutic anticancer potential by triggering distinct molecular cell death mechanisms and innate immunity in mutant p53 non-small cell lung cancer.
Freire Boullosa L, Van Loenhout J, Flieswasser T, De Waele J, Hermans C, Lambrechts H, Cuypers B, Laukens K, Bartholomeus E, Siozopoulou V, De Vos WH, Peeters M, Smits ELJ, Deben C. Freire Boullosa L, et al. Among authors: hermans c. Redox Biol. 2021 Jun;42:101949. doi: 10.1016/j.redox.2021.101949. Epub 2021 Mar 19. Redox Biol. 2021. PMID: 33812801 Free PMC article.
445 results